{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T04:47:04Z","timestamp":1784609224305,"version":"3.55.0"},"reference-count":98,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T00:00:00Z","timestamp":1778716800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T00:00:00Z","timestamp":1783468800000},"content-version":"vor","delay-in-days":55,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100032317","name":"NewAmsterdam Pharma","doi-asserted-by":"publisher","award":["112346"],"award-info":[{"award-number":["112346"]}],"id":[{"id":"10.13039\/100032317","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Diabetol"],"DOI":"10.1186\/s12933-026-03209-w","type":"journal-article","created":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T05:14:45Z","timestamp":1778735685000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Drug targets for lipid modification and risk of type 2 diabetes: a cis-Mendelian randomization study"],"prefix":"10.1186","volume":"25","author":[{"given":"Zekai","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rima D.","family":"Triatin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harold","family":"Snieder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. Floriaan","family":"Schmidt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Ditmarsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John J. P.","family":"Kastelein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robin P. F.","family":"Dullaart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan Albert","family":"Kuivenhoven","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris H. L.","family":"Thio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,14]]},"reference":[{"issue":"10059","key":"3209_CR1","doi-asserted-by":"publisher","first-page":"2532","DOI":"10.1016\/S0140-6736(16)31357-5","volume":"388","author":"R Collins","year":"2016","unstructured":"Collins R, Reith C, Emberson J, Armitage J, Baigent C, Blackwell L, et al. Interpretation of the evidence for the efficacy and safety of statin therapy. Lancet. 2016;388(10059):2532\u201361.","journal-title":"Lancet"},{"issue":"1","key":"3209_CR2","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","volume":"41","author":"F Mach","year":"2020","unstructured":"Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, et al. 2019 ESC\/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS). Eur Heart J. 2020;41(1):111\u201388.","journal-title":"Eur Heart J"},{"issue":"19","key":"3209_CR3","first-page":"1997","volume":"316","author":"CM Mangione","year":"2022","unstructured":"Mangione CM, Barry MJ, Nicholson WK, Cabana M, Chelmow D, Coker TR, et al. Statin use for the primary prevention of cardiovascular disease in adults: US Preventive Services Task Force recommendation statement. JAMA. 2022;316(19):1997\u20132007.","journal-title":"JAMA"},{"issue":"10","key":"3209_CR4","doi-asserted-by":"publisher","first-page":"1924","DOI":"10.2337\/dc09-0738","volume":"32","author":"SN Rajpathak","year":"2009","unstructured":"Rajpathak SN, Kumbhani DJ, Crandall J, Barzilai N, Alderman M, Ridker PM. Statin therapy and risk of developing type 2 diabetes: a meta-analysis. Diabetes Care. 2009;32(10):1924\u20139.","journal-title":"Diabetes Care"},{"issue":"13","key":"3209_CR5","doi-asserted-by":"publisher","first-page":"4725","DOI":"10.3390\/ijms21134725","volume":"21","author":"U Galicia-Garcia","year":"2020","unstructured":"Galicia-Garcia U, Jebari S, Larrea-Sebal A, Uribe KB, Siddiqi H, Ostolaza H, et al. Statin treatment-induced development of type 2 diabetes: from clinical evidence to mechanistic insights. Int J Mol Sci. 2020;21(13):4725.","journal-title":"Int J Mol Sci"},{"issue":"12","key":"3209_CR6","doi-asserted-by":"publisher","first-page":"1562","DOI":"10.1001\/jamainternmed.2021.5714","volume":"181","author":"IA Mansi","year":"2021","unstructured":"Mansi IA, Chansard M, Lingvay I, Zhang S, Halm EA, Alvarez CA. Association of statin therapy initiation with diabetes progression: a retrospective matched-cohort study. JAMA Intern Med. 2021;181(12):1562\u201374.","journal-title":"JAMA Intern Med"},{"key":"3209_CR7","doi-asserted-by":"publisher","first-page":"1239335","DOI":"10.3389\/fendo.2023.1239335","volume":"14","author":"M Laakso","year":"2023","unstructured":"Laakso M, Fernandes Silva L. Statins and risk of type 2 diabetes: mechanism and clinical implications. Front Endocrinol. 2023;14:1239335.","journal-title":"Front Endocrinol"},{"issue":"9733","key":"3209_CR8","doi-asserted-by":"publisher","first-page":"2215","DOI":"10.1016\/S0140-6736(10)60484-9","volume":"375","author":"N Sarwar","year":"2010","unstructured":"The Emerging Risk Factors Collaboration, Sarwar N, Gao P, Seshasai SR, Gobin R, Kaptoge S, et al. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet. 2010;375(9733):2215\u201322.","journal-title":"Lancet"},{"issue":"5","key":"3209_CR9","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1016\/S2213-8587(24)00040-8","volume":"12","author":"Collaboration","year":"2024","unstructured":"Collaboration, CTT. Effects of statin therapy on diagnoses of new-onset diabetes and worsening glycaemia in large-scale randomised blinded statin trials: an individual participant data meta-analysis. Lancet Diabetes Endocrinol. 2024;12(5):306\u201319.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"2","key":"3209_CR10","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1056\/NEJMoa2415879","volume":"393","author":"C Magnussen","year":"2025","unstructured":"Magnussen C, Alegre-Diaz J, Al-Nasser LA, Amouyel P, Aviles-Santa L, Bakker SJL, et al. Global effect of cardiovascular risk factors on lifetime estimates. N Engl J Med. 2025;393(2):125\u201338.","journal-title":"N Engl J Med"},{"issue":"25","key":"3209_CR11","doi-asserted-by":"publisher","first-page":"2387","DOI":"10.1056\/NEJMoa1410489","volume":"372","author":"CP Cannon","year":"2015","unstructured":"Cannon CP, Blazing MA, Giugliano RP, McCagg A, White JA, Theroux P, et al. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med. 2015;372(25):2387\u201397.","journal-title":"N Engl J Med"},{"issue":"7","key":"3209_CR12","doi-asserted-by":"publisher","first-page":"e1003121","DOI":"10.1371\/journal.pmed.1003121","volume":"17","author":"AF Cicero","year":"2020","unstructured":"Cicero AF, Fogacci F, Hernandez AV, Banach M, Lipid Group BPM-AC, et al. Efficacy and safety of bempedoic acid for the treatment of hypercholesterolemia: a systematic review and meta-analysis. PLoS Med. 2020;17(7):e1003121.","journal-title":"PLoS Med"},{"issue":"3","key":"3209_CR13","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1038\/s41569-018-0107-8","volume":"16","author":"MS Sabatine","year":"2019","unstructured":"Sabatine MS. PCSK9 inhibitors: clinical evidence and implementation. Nat Rev Cardiol. 2019;16(3):155\u201365.","journal-title":"Nat Rev Cardiol"},{"issue":"1","key":"3209_CR14","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1007\/s11883-024-01269-5","volume":"27","author":"DJ Blom","year":"2024","unstructured":"Blom DJ, Marais AD, Raal FJ. Homozygous familial hypercholesterolemia treatment: new developments. Curr Atheroscler Rep. 2024;27(1):22.","journal-title":"Curr Atheroscler Rep"},{"issue":"25","key":"3209_CR15","doi-asserted-by":"publisher","first-page":"2277","DOI":"10.1093\/eurheartj\/ehad197","volume":"44","author":"M Cuchel","year":"2023","unstructured":"Cuchel M, Raal FJ, Hegele RA, Al-Rasadi K, Arca M, Averna M, et al. 2023 update on European atherosclerosis society consensus statement on homozygous familial hypercholesterolaemia: new treatments and clinical guidance. Eur Heart J. 2023;44(25):2277\u201391.","journal-title":"Eur Heart J"},{"issue":"1","key":"3209_CR16","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.1007\/s11033-024-10003-y","volume":"51","author":"U Munkhsaikhan","year":"2024","unstructured":"Munkhsaikhan U, Ait-Aissa K, Sahyoun AM, Apu EH, Abidi AH, Kassan A, et al. Lomitapide: navigating cardiovascular challenges with innovative therapies. Mol Biol Rep. 2024;51(1):1082.","journal-title":"Mol Biol Rep"},{"issue":"3","key":"3209_CR17","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1056\/NEJMoa1612790","volume":"377","author":"FE Dewey","year":"2017","unstructured":"Dewey FE, Gusarova V, Dunbar RL, O\u2019Dushlaine C, Schurmann C, Gottesman O, et al. Genetic and pharmacologic inactivation of ANGPTL3 and cardiovascular disease. N Engl J Med. 2017;377(3):211\u201321.","journal-title":"N Engl J Med"},{"issue":"10","key":"3209_CR18","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1056\/NEJMoa2404147","volume":"391","author":"RS Rosenson","year":"2024","unstructured":"Rosenson RS, Gaudet D, Hegele RA, Ballantyne CM, Nicholls SJ, Lucas KJ, et al. Zodasiran, an RNAi therapeutic targeting ANGPTL3, for mixed hyperlipidemia. N Engl J Med. 2024;391(10):913\u201325.","journal-title":"N Engl J Med"},{"issue":"19","key":"3209_CR19","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.1016\/j.jacc.2025.03.005","volume":"85","author":"K Ray Kausik","year":"2025","unstructured":"Ray Kausik K, Linnebjerg H, Michael Laura F, Shen X, Ma X, Lim S, et al. Effect of ANGPTL3 inhibition with solbinsiran in preclinical and early human studies. JACC. 2025;85(19):1803\u201318.","journal-title":"JACC"},{"issue":"6","key":"3209_CR20","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1056\/NEJMoa1715944","volume":"381","author":"JL Witztum","year":"2019","unstructured":"Witztum JL, Gaudet D, Freedman SD, Alexander VJ, Digenio A, Williams KR, et al. Volanesorsen and triglyceride levels in familial chylomicronemia syndrome. N Engl J Med. 2019;381(6):531\u201342.","journal-title":"N Engl J Med"},{"issue":"19","key":"3209_CR21","doi-asserted-by":"publisher","first-page":"1770","DOI":"10.1056\/NEJMoa2402309","volume":"390","author":"BA Bergmark","year":"2024","unstructured":"Bergmark BA, Marston NA, Prohaska TA, Alexander VJ, Zimerman A, Moura FA, et al. Olezarsen for hypertriglyceridemia in patients at high cardiovascular risk. N Engl J Med. 2024;390(19):1770\u201380.","journal-title":"N Engl J Med"},{"issue":"10","key":"3209_CR22","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1056\/NEJMoa2404143","volume":"391","author":"CM Ballantyne","year":"2024","unstructured":"Ballantyne CM, Vasas S, Azizad M, Clifton P, Rosenson RS, Chang T, et al. Plozasiran, an RNA interference agent targeting APOC3, for mixed hyperlipidemia. N Engl J Med. 2024;391(10):899\u2013912.","journal-title":"N Engl J Med"},{"key":"3209_CR23","doi-asserted-by":"publisher","first-page":"1923","DOI":"10.1016\/S0140-6736(25)00825-6","volume":"405","author":"BB Cummings","year":"2025","unstructured":"Cummings BB, Joing MP, Bouchard PR, Milton MN, Moesta PF, Ramanan V, et al. Safety and efficacy of a novel ANGPTL4 inhibitory antibody for lipid lowering: results from phase 1 and phase 1b\/2a clinical studies. Lancet. 2025;405:1923\u201334.","journal-title":"Lancet"},{"issue":"12","key":"3209_CR24","doi-asserted-by":"publisher","first-page":"3005","DOI":"10.1161\/ATVBAHA.120.315757","volume":"41","author":"CT Ruff","year":"2021","unstructured":"Ruff CT, Koren MJ, Grimsby J, Rosenbaum AI, Tu X, Karathanasis SK, et al. LEGACY: phase 2a trial to evaluate the safety, pharmacokinetics, and pharmacodynamic effects of the anti-EL (Endothelial Lipase) antibody MEDI5884 in patients with stable coronary artery disease. Arterioscler Thromb Vasc Biol. 2021;41(12):3005\u201314.","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"1","key":"3209_CR25","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1161\/CIRCRESAHA.117.311145","volume":"121","author":"A Nomura","year":"2017","unstructured":"Nomura A, Won HH, Khera AV, Takeuchi F, Ito K, McCarthy S, et al. Protein-truncating variants at the cholesteryl ester transfer protein gene and risk for coronary heart disease. Circ Res. 2017;121(1):81\u20138.","journal-title":"Circ Res"},{"issue":"13","key":"3209_CR26","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1056\/NEJMoa1706444","volume":"377","author":"L Bowman","year":"2017","unstructured":"Group HTRC, Bowman L, Hopewell JC, Chen F, Wallendszus K, Stevens W, et al. Effects of anacetrapib in patients with atherosclerotic vascular disease. N Engl J Med. 2017;377(13):1217\u201327.","journal-title":"N Engl J Med"},{"issue":"20","key":"3209_CR27","doi-asserted-by":"publisher","first-page":"1933","DOI":"10.1056\/NEJMoa1609581","volume":"376","author":"AM Lincoff","year":"2017","unstructured":"Lincoff AM, Nicholls SJ, Riesmeyer JS, Barter PJ, Brewer HB, Fox KAA, et al. Evacetrapib and cardiovascular outcomes in high-risk vascular disease. N Engl J Med. 2017;376(20):1933\u201342.","journal-title":"N Engl J Med"},{"issue":"7809","key":"3209_CR28","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1038\/s41586-020-2267-z","volume":"581","author":"EV Minikel","year":"2020","unstructured":"Minikel EV, Karczewski KJ, Martin HC, Cummings BB, Whiffin N, Rhodes D, et al. Evaluating drug targets through human loss-of-function genetic variation. Nature. 2020;581(7809):459\u201364.","journal-title":"Nature"},{"issue":"1","key":"3209_CR29","doi-asserted-by":"publisher","first-page":"5640","DOI":"10.1038\/s41467-021-25703-3","volume":"12","author":"AF Schmidt","year":"2021","unstructured":"Schmidt AF, Hunt NB, Gordillo-Maranon M, Charoen P, Drenos F, Kivimaki M, et al. Cholesteryl ester transfer protein (CETP) as a drug target for cardiovascular disease. Nat Commun. 2021;12(1):5640.","journal-title":"Nat Commun"},{"issue":"2","key":"3209_CR30","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1007\/s11883-023-01184-1","volume":"26","author":"JJP Kastelein","year":"2024","unstructured":"Kastelein JJP, Hsieh A, Dicklin MR, Ditmarsch M, Davidson MH. Obicetrapib: reversing the tide of CETP inhibitor disappointments. Curr Atheroscler Rep. 2024;26(2):35\u201344.","journal-title":"Curr Atheroscler Rep"},{"issue":"6","key":"3209_CR31","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1161\/CIRCULATIONAHA.124.069210","volume":"151","author":"A Greco","year":"2025","unstructured":"Greco A, Finocchiaro S, Spagnolo M, Faro DC, Mauro MS, Raffo C, et al. Lipoprotein (a) as a pharmacological target: premises, promises, and prospects. Circulation. 2025;151(6):400\u201315.","journal-title":"Circulation"},{"issue":"22","key":"3209_CR32","doi-asserted-by":"publisher","first-page":"2144","DOI":"10.1056\/NEJMoa1604304","volume":"375","author":"BA Ference","year":"2016","unstructured":"Ference BA, Robinson JG, Brook RD, Catapano AL, Chapman MJ, Neff DR, et al. Variation in PCSK9 and HMGCR and risk of cardiovascular disease and diabetes. N Engl J Med. 2016;375(22):2144\u201353.","journal-title":"N Engl J Med"},{"issue":"13","key":"3209_CR33","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1001\/jama.2016.14568","volume":"316","author":"LA Lotta","year":"2016","unstructured":"Lotta LA, Sharp SJ, Burgess S, Perry JRB, Stewart ID, Willems SM, et al. Association between low-density lipoprotein cholesterol-lowering genetic variants and risk of type 2 diabetes: a meta-analysis. JAMA. 2016;316(13):1383\u201391.","journal-title":"JAMA"},{"issue":"2","key":"3209_CR34","doi-asserted-by":"publisher","first-page":"364","DOI":"10.2337\/dc17-1464","volume":"41","author":"LSF de Carvalho","year":"2018","unstructured":"de Carvalho LSF, Campos AM, Sposito AC. Proprotein convertase subtilisin\/kexin type 9 (PCSK9) inhibitors and incident type 2 diabetes: a systematic review and meta-analysis with over 96,000 patient-years. Diabetes Care. 2018;41(2):364\u20137.","journal-title":"Diabetes Care"},{"issue":"1","key":"3209_CR35","doi-asserted-by":"publisher","first-page":"e002196","DOI":"10.1161\/CIRCGEN.118.002196","volume":"12","author":"CP Nelson","year":"2019","unstructured":"Nelson CP, Lai FY, Nath M, Ye S, Webb TR, Schunkert H, et al. Genetic assessment of potential long-term on-target side effects of PCSK9 (proprotein convertase subtilisin\/kexin type 9) inhibitors. Circ Genom Precis Med. 2019;12(1):e002196.","journal-title":"Circ Genom Precis Med"},{"issue":"12","key":"3209_CR36","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1007\/s11883-022-01074-y","volume":"24","author":"S Carugo","year":"2022","unstructured":"Carugo S, Sirtori CR, Corsini A, Tokgozoglu L, Ruscica M. PCSK9 inhibition and risk of diabetes: should we worry? Curr Atheroscler Rep. 2022;24(12):995\u20131004.","journal-title":"Curr Atheroscler Rep"},{"key":"3209_CR37","doi-asserted-by":"publisher","first-page":"117444","DOI":"10.1016\/j.cca.2023.117444","volume":"547","author":"JN Xu","year":"2023","unstructured":"Xu JN, Wang TT, Shu H, Shi SY, Tao LC, Li JJ. Insight into the role of PCSK9 in glucose metabolism. Clin Chim Acta. 2023;547:117444.","journal-title":"Clin Chim Acta"},{"issue":"6","key":"3209_CR38","first-page":"622","volume":"8","author":"K Dangas","year":"2022","unstructured":"Dangas K, Navar A-M, Kastelein JJ. The effect of CETP inhibitors on new-onset diabetes: a systematic review and meta-analysis. Eur Heart J. 2022;8(6):622\u201332.","journal-title":"Eur Heart J"},{"issue":"5","key":"3209_CR39","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1177\/1074248420924983","volume":"25","author":"SW Chiu","year":"2020","unstructured":"Chiu SW, Pratt CM, Feinn R, Chatterjee S. Proprotein convertase subtilisin\/kexin type 9 inhibitors and ezetimibe on risk of new-onset diabetes: a systematic review and meta-analysis of large, double-blinded randomized controlled trials. J Cardiovasc Pharmacol Ther. 2020;25(5):409\u201317.","journal-title":"J Cardiovasc Pharmacol Ther"},{"issue":"13","key":"3209_CR40","doi-asserted-by":"publisher","first-page":"e029593","DOI":"10.1161\/JAHA.122.029593","volume":"12","author":"NP Shah","year":"2023","unstructured":"Shah NP, McGuire DK, Cannon CP, Giugliano RP, Lokhnygina Y, Page CB, et al. Impact of ezetimibe on new\u2010onset diabetes: a substudy of IMPROVE\u2010IT. J Am Heart Assoc. 2023;12(13):e029593.","journal-title":"J Am Heart Assoc"},{"issue":"2","key":"3209_CR41","doi-asserted-by":"publisher","first-page":"e3001547","DOI":"10.1371\/journal.pbio.3001547","volume":"20","author":"TG Richardson","year":"2022","unstructured":"Richardson TG, Leyden GM, Wang Q, Bell JA, Elsworth B, Davey Smith G, et al. Characterising metabolomic signatures of lipid-modifying therapies through drug target mendelian randomisation. PLoS Biol. 2022;20(2):e3001547.","journal-title":"PLoS Biol"},{"key":"3209_CR42","doi-asserted-by":"publisher","first-page":"117501","DOI":"10.1016\/j.atherosclerosis.2024.117501","volume":"391","author":"E Gagnon","year":"2024","unstructured":"Gagnon E, Arsenault BJ. Drug target Mendelian randomization supports apolipoprotein C3-lowering for lipoprotein-lipid levels reductions and cardiovascular diseases prevention. Atherosclerosis. 2024;391:117501.","journal-title":"Atherosclerosis"},{"issue":"12","key":"3209_CR43","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.1093\/eurheartj\/ehaa972","volume":"42","author":"Q Wang","year":"2021","unstructured":"Wang Q, Oliver-Williams C, Raitakari OT, Viikari J, Lehtim\u00e4ki T, K\u00e4h\u00f6nen M, et al. Metabolic profiling of angiopoietin-like protein 3 and 4 inhibition: a drug-target Mendelian randomization analysis. Eur Heart J. 2021;42(12):1160\u20139.","journal-title":"Eur Heart J"},{"issue":"3","key":"3209_CR44","doi-asserted-by":"publisher","first-page":"oeae035","DOI":"10.1093\/ehjopen\/oeae035","volume":"4","author":"F Landfors","year":"2024","unstructured":"Landfors F, Henneman P, Chorell E, Nilsson SK, Kersten S. Drug-target Mendelian randomization analysis supports lowering plasma ANGPTL3, ANGPTL4, and APOC3 levels as strategies for reducing cardiovascular disease risk. Eur Heart J Open. 2024;4(3):oeae035.","journal-title":"Eur Heart J Open"},{"key":"3209_CR45","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.athplu.2024.07.001","volume":"57","author":"MW Yeung","year":"2024","unstructured":"Yeung MW, Said MA, van de Vegte YJ, Verweij N, Dullaart RP, van der Harst P. Associations of very low lipoprotein (a) levels with risks of new-onset diabetes and non-alcoholic liver disease. Atheroscler Plus. 2024;57:19\u201325.","journal-title":"Atheroscler Plus"},{"issue":"R1","key":"3209_CR46","doi-asserted-by":"publisher","first-page":"R89","DOI":"10.1093\/hmg\/ddu328","volume":"23","author":"G Davey Smith","year":"2014","unstructured":"Davey Smith G, Hemani G. Mendelian randomization: genetic anchors for causal inference in epidemiological studies. Hum Mol Genet. 2014;23(R1):R89\u201398.","journal-title":"Hum Mol Genet"},{"issue":"1","key":"3209_CR47","doi-asserted-by":"publisher","first-page":"3255","DOI":"10.1038\/s41467-020-16969-0","volume":"11","author":"AF Schmidt","year":"2020","unstructured":"Schmidt AF, Finan C, Gordillo-Maranon M, Asselbergs FW, Freitag DF, Patel RS, et al. Genetic drug target validation using Mendelian randomisation. Nat Commun. 2020;11(1):3255.","journal-title":"Nat Commun"},{"key":"3209_CR48","doi-asserted-by":"publisher","first-page":"16","DOI":"10.12688\/wellcomeopenres.16544.1","volume":"6","author":"D Gill","year":"2021","unstructured":"Gill D, Georgakis MK, Walker VM, Schmidt AF, Gkatzionis A, Freitag DF, et al. Mendelian randomization for studying the effects of perturbing drug targets. Wellcome Open Res. 2021;6:16.","journal-title":"Wellcome Open Res"},{"issue":"D1","key":"3209_CR49","doi-asserted-by":"publisher","first-page":"D933","DOI":"10.1093\/nar\/gkac958","volume":"51","author":"FJ Martin","year":"2023","unstructured":"Martin FJ, Amode MR, Aneja A, Austine-Orimoloye O, Azov AG, Barnes I, et al. Ensembl 2023. Nucleic Acids Res. 2023;51(D1):D933\u201341.","journal-title":"Nucleic Acids Res"},{"key":"3209_CR50","doi-asserted-by":"publisher","first-page":"186","DOI":"10.12688\/wellcomeopenres.15555.1","volume":"4","author":"S Burgess","year":"2019","unstructured":"Burgess S, Davey Smith G, Davies NM, Dudbridge F, Gill D, Glymour MM, et al. Guidelines for performing Mendelian randomization investigations: update for summer 2023. Wellcome Open Res. 2019;4:186.","journal-title":"Wellcome Open Res"},{"key":"3209_CR51","doi-asserted-by":"publisher","DOI":"10.1038\/s43586-021-00092-5","author":"E Sanderson","year":"2022","unstructured":"Sanderson E, Glymour MM, Holmes MV, Kang H, Morrison J, Munafo MR, et al. Mendelian randomization. Nat Rev Methods Primers. 2022. https:\/\/doi.org\/10.1038\/s43586-021-00092-5.","journal-title":"Nat Rev Methods Primers"},{"key":"3209_CR52","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a039230","author":"AF Schmidt","year":"2022","unstructured":"Schmidt AF, Hingorani AD, Finan C. Human genomics and drug development. Cold Spring Harb Perspect Med. 2022. https:\/\/doi.org\/10.1101\/cshperspect.a039230.","journal-title":"Cold Spring Harb Perspect Med"},{"issue":"1","key":"3209_CR53","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1002\/gepi.22506","volume":"47","author":"A Gkatzionis","year":"2023","unstructured":"Gkatzionis A, Burgess S, Newcombe PJ. Statistical methods for cis-Mendelian randomization with two-sample summary-level data. Genet Epidemiol. 2023;47(1):3\u201325.","journal-title":"Genet Epidemiol"},{"issue":"1","key":"3209_CR54","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1186\/s12916-024-03700-9","volume":"22","author":"D Gill","year":"2024","unstructured":"Gill D, Dib MJ, Cronje HT, Karhunen V, Woolf B, Gagnon E, et al. Common pitfalls in drug target Mendelian randomization and how to avoid them. BMC Med. 2024;22(1):473.","journal-title":"BMC Med"},{"issue":"0","key":"3209_CR55","first-page":"e005336","volume":"0","author":"JL Ciofani","year":"2025","unstructured":"Ciofani JL, Han D, Bhindi R. Drug target Mendelian randomization: distinguishing between causal mechanisms and biomarkers of those mechanisms. Circ Genom Precis Med. 2025;0(0):e005336.","journal-title":"Circ Genom Precis Med"},{"issue":"3","key":"3209_CR56","doi-asserted-by":"publisher","first-page":"e1003062","DOI":"10.1371\/journal.pmed.1003062","volume":"17","author":"TG Richardson","year":"2020","unstructured":"Richardson TG, Sanderson E, Palmer TM, Ala-Korpela M, Ference BA, Davey Smith G, et al. Evaluating the relationship between circulating lipoprotein lipids and apolipoproteins with risk of coronary heart disease: a multivariable Mendelian randomisation analysis. PLoS Med. 2020;17(3):e1003062.","journal-title":"PLoS Med"},{"issue":"5","key":"3209_CR57","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1038\/s41588-022-01058-3","volume":"54","author":"A Mahajan","year":"2022","unstructured":"Mahajan A, Spracklen CN, Zhang W, Ng MCY, Petty LE, Kitajima H, et al. Multi-ancestry genetic study of type 2 diabetes highlights the power of diverse populations for discovery and translation. Nat Genet. 2022;54(5):560\u201372.","journal-title":"Nat Genet"},{"issue":"7944","key":"3209_CR58","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1038\/s41586-022-05473-8","volume":"613","author":"MI Kurki","year":"2023","unstructured":"Kurki MI, Karjalainen J, Palta P, Sipila TP, Kristiansson K, Donner KM, et al. FinnGen provides genetic insights from a well-phenotyped isolated population. Nature. 2023;613(7944):508\u201318.","journal-title":"Nature"},{"issue":"12","key":"3209_CR59","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.1038\/s41588-022-01233-6","volume":"54","author":"KG Aragam","year":"2022","unstructured":"Aragam KG, Jiang T, Goel A, Kanoni S, Wolford BN, Atri DS, et al. Discovery and systematic characterization of risk variants and genes for coronary artery disease in over a million participants. Nat Genet. 2022;54(12):1803\u201315.","journal-title":"Nat Genet"},{"issue":"9","key":"3209_CR60","doi-asserted-by":"publisher","first-page":"1448","DOI":"10.1038\/s41588-023-01462-3","volume":"55","author":"V Lagou","year":"2023","unstructured":"Lagou V, Jiang L, Ulrich A, Zudina L, Gonzalez KSG, Balkhiyarova Z, et al. GWAS of random glucose in 476,326 individuals provide insights into diabetes pathophysiology, complications and treatment stratification. Nat Genet. 2023;55(9):1448\u201361.","journal-title":"Nat Genet"},{"issue":"6","key":"3209_CR61","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1038\/s41588-021-00852-9","volume":"53","author":"J Chen","year":"2021","unstructured":"Chen J, Spracklen CN, Marenne G, Varshney A, Corbin LJ, Luan J, et al. The trans-ancestral genomic architecture of glycemic traits. Nat Genet. 2021;53(6):840\u201360.","journal-title":"Nat Genet"},{"issue":"2","key":"3209_CR62","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1038\/ng.520","volume":"42","author":"J Dupuis","year":"2010","unstructured":"Dupuis J, Langenberg C, Prokopenko I, Saxena R, Soranzo N, Jackson AU, et al. New genetic loci implicated in fasting glucose homeostasis and their impact on type 2 diabetes risk. Nat Genet. 2010;42(2):105\u201316.","journal-title":"Nat Genet"},{"key":"3209_CR63","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.34408","author":"G Hemani","year":"2018","unstructured":"Hemani G, Zheng J, Elsworth B, Wade KH, Haberland V, Baird D, et al. The MR-Base platform supports systematic causal inference across the human phenome. Elife. 2018. https:\/\/doi.org\/10.7554\/eLife.34408.","journal-title":"Elife"},{"issue":"6","key":"3209_CR64","doi-asserted-by":"publisher","first-page":"1734","DOI":"10.1093\/ije\/dyx034","volume":"46","author":"OO Yavorska","year":"2017","unstructured":"Yavorska OO, Burgess S. Mendelian Randomization: an R package for performing Mendelian randomization analyses using summarized data. Int J Epidemiol. 2017;46(6):1734\u20139.","journal-title":"Int J Epidemiol"},{"issue":"2","key":"3209_CR65","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1038\/s41588-024-02044-7","volume":"57","author":"H Loya","year":"2025","unstructured":"Loya H, Kalantzis G, Cooper F, Palamara PF. A scalable variational inference approach for increased mixed-model association power. Nat Genet. 2025;57(2):461\u20138.","journal-title":"Nat Genet"},{"issue":"6509","key":"3209_CR66","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.1126\/science.aaz1776","volume":"369","author":"GTEx Consortium","year":"2020","unstructured":"GTEx Consortium. The GTEx Consortium atlas of genetic regulatory effects across human tissues. Science. 2020;369(6509):1318\u201330.","journal-title":"Science"},{"key":"3209_CR67","doi-asserted-by":"publisher","first-page":"n2233","DOI":"10.1136\/bmj.n2233","volume":"375","author":"VW Skrivankova","year":"2021","unstructured":"Skrivankova VW, Richmond RC, Woolf BAR, Davies NM, Swanson SA, VanderWeele TJ, et al. Strengthening the reporting of observational studies in epidemiology using mendelian randomisation (STROBE-MR): explanation and elaboration. BMJ. 2021;375:n2233.","journal-title":"BMJ"},{"issue":"16","key":"3209_CR68","doi-asserted-by":"publisher","first-page":"1614","DOI":"10.1001\/jama.2021.18236","volume":"326","author":"VW Skrivankova","year":"2021","unstructured":"Skrivankova VW, Richmond RC, Woolf BAR, Yarmolinsky J, Davies NM, Swanson SA, et al. Strengthening the reporting of observational studies in epidemiology using Mendelian randomization: the STROBE-MR statement. JAMA. 2021;326(16):1614\u201321.","journal-title":"JAMA"},{"issue":"5","key":"3209_CR69","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1016\/j.ajhg.2022.04.001","volume":"109","author":"V Zuber","year":"2022","unstructured":"Zuber V, Grinberg NF, Gill D, Manipur I, Slob EAW, Patel A, et al. Combining evidence from Mendelian randomization and colocalization: review and comparison of approaches. Am J Hum Genet. 2022;109(5):767\u201382.","journal-title":"Am J Hum Genet"},{"issue":"5","key":"3209_CR70","doi-asserted-by":"publisher","first-page":"e1004383","DOI":"10.1371\/journal.pgen.1004383","volume":"10","author":"C Giambartolomei","year":"2014","unstructured":"Giambartolomei C, Vukcevic D, Schadt EE, Franke L, Hingorani AD, Wallace C, et al. Bayesian test for colocalisation between pairs of genetic association studies using summary statistics. PLoS Genet. 2014;10(5):e1004383.","journal-title":"PLoS Genet"},{"issue":"21","key":"3209_CR71","doi-asserted-by":"publisher","first-page":"3555","DOI":"10.1093\/bioinformatics\/btv402","volume":"31","author":"MJ Machiela","year":"2015","unstructured":"Machiela MJ, Chanock SJ. LDlink: a web-based application for exploring population-specific haplotype structure and linking correlated alleles of possible functional variants. Bioinformatics. 2015;31(21):3555\u20137.","journal-title":"Bioinformatics"},{"issue":"7571","key":"3209_CR72","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1038\/nature15393","volume":"526","author":"The 1000 Genomes Project Consortium","year":"2015","unstructured":"The 1000 Genomes Project Consortium. A global reference for human genetic variation. Nature. 2015;526(7571):68.","journal-title":"Nature"},{"issue":"9","key":"3209_CR73","doi-asserted-by":"publisher","first-page":"e1009440","DOI":"10.1371\/journal.pgen.1009440","volume":"17","author":"C Wallace","year":"2021","unstructured":"Wallace C. A more accurate method for colocalisation analysis allowing for multiple causal variants. PLoS Genet. 2021;17(9):e1009440.","journal-title":"PLoS Genet"},{"issue":"2","key":"3209_CR74","doi-asserted-by":"publisher","first-page":"e004933","DOI":"10.1161\/CIRCGEN.124.004933","volume":"18","author":"E Gagnon","year":"2025","unstructured":"Gagnon E, Gill D, Chabot D, Cronj\u00e9 HT, Yuan S, Brennan S, et al. Evaluating the cardiometabolic efficacy and safety of lipoprotein lipase pathway targets in combination with approved lipid-lowering targets: a drug target mendelian randomization study. Circ Genom Precis Med. 2025;18(2):e004933.","journal-title":"Circ Genom Precis Med"},{"issue":"6","key":"3209_CR75","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1038\/ng.3561","volume":"48","author":"A Helgadottir","year":"2016","unstructured":"Helgadottir A, Gretarsdottir S, Thorleifsson G, Hjartarson E, Sigurdsson A, Magnusdottir A, et al. Variants with large effects on blood lipids and the role of cholesterol and triglycerides in coronary disease. Nat Genet. 2016;48(6):634\u20139.","journal-title":"Nat Genet"},{"issue":"16","key":"3209_CR76","doi-asserted-by":"publisher","first-page":"2054","DOI":"10.1016\/j.jacc.2017.02.030","volume":"69","author":"NO Stitziel","year":"2017","unstructured":"Stitziel NO, Khera AV, Wang X, Bierhals AJ, Vourakis AC, Sperry AE, et al. ANGPTL3 deficiency and protection against coronary artery disease. J Am Coll Cardiol. 2017;69(16):2054\u201363.","journal-title":"J Am Coll Cardiol"},{"key":"3209_CR77","doi-asserted-by":"publisher","unstructured":"Gobeil \u00c9, Bourgault J, Mitchell PL, Houessou U, Gagnon E, Girard A, et al. Genetic inhibition of angiopoietin-like protein-3, lipoprotein-lipid levels and cardiometabolic diseases. 2023. medRxiv. https:\/\/doi.org\/10.1101\/2023.05.29.23290580.","DOI":"10.1101\/2023.05.29.23290580"},{"key":"3209_CR78","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.atherosclerosis.2021.04.014","volume":"327","author":"LF Reeskamp","year":"2021","unstructured":"Reeskamp LF, Nurmohamed NS, Bom MJ, Planken RN, Driessen RS, van Diemen PA, et al. Marked plaque regression in homozygous familial hypercholesterolemia. Atherosclerosis. 2021;327:13\u20137.","journal-title":"Atherosclerosis"},{"issue":"6","key":"3209_CR79","doi-asserted-by":"publisher","first-page":"1447","DOI":"10.1161\/ATVBAHA.123.320609","volume":"44","author":"S B\u00e9liard","year":"2024","unstructured":"B\u00e9liard S, Saheb S, Litzler-Renault S, Vimont A, Valero R, Bruckert \u00c9, et al. Evinacumab and cardiovascular outcome in patients with homozygous familial hypercholesterolemia. Arterioscler Thromb Vasc Biol. 2024;44(6):1447\u201354.","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"1","key":"3209_CR80","doi-asserted-by":"publisher","first-page":"2252","DOI":"10.1038\/s41467-018-04611-z","volume":"9","author":"V Gusarova","year":"2018","unstructured":"Gusarova V, O\u2019Dushlaine C, Teslovich TM, Benotti PN, Mirshahi T, Gottesman O, et al. Genetic inactivation of ANGPTL4 improves glucose homeostasis and is associated with reduced risk of diabetes. Nat Commun. 2018;9(1):2252.","journal-title":"Nat Commun"},{"key":"3209_CR81","doi-asserted-by":"publisher","first-page":"117558","DOI":"10.1016\/j.atherosclerosis.2024.117558","volume":"393","author":"E Gagnon","year":"2024","unstructured":"Gagnon E, Bourgault J, Gobeil \u00c9, Th\u00e9riault S, Arsenault BJ. Impact of loss-of-function in angiopoietin-like 4 on the human phenome. Atherosclerosis. 2024;393:117558.","journal-title":"Atherosclerosis"},{"key":"3209_CR82","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1016\/j.bbrc.2020.11.053","volume":"534","author":"YQ Chen","year":"2021","unstructured":"Chen YQ, Pottanat TG, Siegel RW, Ehsani M, Qian Y-W, Roell WC, et al. Angiopoietin-like protein 4(E40K) and ANGPTL4\/8 complex have reduced, temperature-dependent LPL-inhibitory activity compared to ANGPTL4. Biochem Biophys Res Commun. 2021;534:498\u2013503.","journal-title":"Biochem Biophys Res Commun"},{"issue":"6","key":"3209_CR83","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1097\/MOL.0000000000000789","volume":"32","author":"S Kersten","year":"2021","unstructured":"Kersten S. ANGPTL3 as therapeutic target. Curr Opin Lipidol. 2021;32(6):335\u201341.","journal-title":"Curr Opin Lipidol"},{"key":"3209_CR84","doi-asserted-by":"publisher","first-page":"100112","DOI":"10.1016\/j.jlr.2021.100112","volume":"62","author":"KL Sylvers-Davie","year":"2021","unstructured":"Sylvers-Davie KL, Segura-Roman A, Salvi AM, Schache KJ, Davies BSJ. Angiopoietin-like 3 inhibition of endothelial lipase is not modulated by angiopoietin-like 8. J Lipid Res. 2021;62:100112.","journal-title":"J Lipid Res"},{"issue":"1","key":"3209_CR85","doi-asserted-by":"publisher","first-page":"100313","DOI":"10.1016\/j.jlr.2022.100313","volume":"64","author":"F Landfors","year":"2023","unstructured":"Landfors F, Chorell E, Kersten S. Genetic mimicry analysis reveals the specific lipases targeted by the ANGPTL3-ANGPTL8 complex and ANGPTL4. J Lipid Res. 2023;64(1):100313.","journal-title":"J Lipid Res"},{"issue":"12","key":"3209_CR86","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1056\/NEJMoa1510926","volume":"374","author":"FE Dewey","year":"2016","unstructured":"Dewey FE, Gusarova V, O\u2019Dushlaine C, Gottesman O, Trejos J, Hunt C, et al. Inactivating variants in ANGPTL4 and risk of coronary artery disease. N Engl J Med. 2016;374(12):1123\u201333.","journal-title":"N Engl J Med"},{"issue":"12","key":"3209_CR87","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1056\/NEJMoa1507652","volume":"374","author":"NO Stitziel","year":"2016","unstructured":"Stitziel NO, Stirrups KE, Masca NG, Erdmann J, Ferrario PG, K\u00f6nig IR, et al. Coding variation in ANGPTL4, LPL, and SVEP1 and the risk of coronary disease. N Engl J Med. 2016;374(12):1134\u201344.","journal-title":"N Engl J Med"},{"key":"3209_CR88","doi-asserted-by":"publisher","first-page":"100150","DOI":"10.1016\/j.jlr.2021.100150","volume":"62","author":"S Kersten","year":"2021","unstructured":"Kersten S. Role and mechanism of the action of angiopoietin-like protein ANGPTL4 in plasma lipid metabolism. J Lipid Res. 2021;62:100150.","journal-title":"J Lipid Res"},{"issue":"23","key":"3209_CR89","doi-asserted-by":"publisher","first-page":"2200","DOI":"10.1056\/NEJMoa1400284","volume":"371","author":"D Gaudet","year":"2014","unstructured":"Gaudet D, Brisson D, Tremblay K, Alexander VJ, Singleton W, Hughes SG, et al. Targeting APOC3 in the familial chylomicronemia syndrome. N Engl J Med. 2014;371(23):2200\u20136.","journal-title":"N Engl J Med"},{"issue":"8","key":"3209_CR90","doi-asserted-by":"publisher","first-page":"2855","DOI":"10.1172\/JCI86610","volume":"126","author":"PL Gordts","year":"2016","unstructured":"Gordts PL, Nock R, Son NH, Ramms B, Lew I, Gonzales JC, et al. ApoC-III inhibits clearance of triglyceride-rich lipoproteins through LDL family receptors. J Clin Invest. 2016;126(8):2855\u201366.","journal-title":"J Clin Invest"},{"issue":"7","key":"3209_CR91","doi-asserted-by":"publisher","first-page":"100237","DOI":"10.1016\/j.jlr.2022.100237","volume":"63","author":"M Deng","year":"2022","unstructured":"Deng M, Kutrolli E, Sadewasser A, Michel S, Joibari MM, Jaschinski F, et al. ANGPTL4 silencing via antisense oligonucleotides reduces plasma triglycerides and glucose in mice without causing lymphadenopathy. J Lipid Res. 2022;63(7):100237.","journal-title":"J Lipid Res"},{"issue":"17","key":"3209_CR92","doi-asserted-by":"publisher","first-page":"2179","DOI":"10.1093\/cvr\/cvae195","volume":"120","author":"M Modder","year":"2024","unstructured":"Modder M, Het Panhuis WI, Li M, Afkir S, Dorn AL, Pronk ACM, et al. Liver-targeted Angptl4 silencing by antisense oligonucleotide treatment attenuates hyperlipidaemia and atherosclerosis development in APOE*3-Leiden.CETP mice. Cardiovasc Res. 2024;120(17):2179\u201390.","journal-title":"Cardiovasc Res"},{"issue":"11","key":"3209_CR93","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1038\/nrcardio.2017.156","volume":"14","author":"MV Holmes","year":"2017","unstructured":"Holmes MV, Smith GD. Dyslipidaemia: revealing the effect of CETP inhibition in cardiovascular disease. Nat Rev Cardiol. 2017;14(11):635\u20136.","journal-title":"Nat Rev Cardiol"},{"issue":"1","key":"3209_CR94","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1161\/CIRCRESAHA.117.311978","volume":"122","author":"AR Tall","year":"2018","unstructured":"Tall AR, Rader DJ. Trials and tribulations of CETP inhibitors. Circ Res. 2018;122(1):106\u201312.","journal-title":"Circ Res"},{"issue":"1","key":"3209_CR95","doi-asserted-by":"publisher","first-page":"a040501","DOI":"10.1101\/cshperspect.a040501","volume":"12","author":"RC Richmond","year":"2022","unstructured":"Richmond RC, Davey Smith G. Mendelian randomization: concepts and scope. Cold Spring Harb Perspect Med. 2022;12(1):a040501.","journal-title":"Cold Spring Harb Perspect Med"},{"key":"3209_CR96","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a040980","author":"BA Ference","year":"2021","unstructured":"Ference BA, Holmes MV, Smith GD. Using Mendelian randomization to improve the design of randomized trials. Cold Spring Harb Perspect Med. 2021. https:\/\/doi.org\/10.1101\/cshperspect.a040980.","journal-title":"Cold Spring Harb Perspect Med"},{"issue":"1","key":"3209_CR97","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/ije\/dyg070","volume":"32","author":"GD Smith","year":"2003","unstructured":"Smith GD, Ebrahim S. \u2018Mendelian randomization\u2019: can genetic epidemiology contribute to understanding environmental determinants of disease? Int J Epidemiol. 2003;32(1):1\u201322.","journal-title":"Int J Epidemiol"},{"key":"3209_CR98","doi-asserted-by":"publisher","unstructured":"Hwang S, Pullin J, Wallace C, Whittaker J, Burgess S. Systematic comparison of colocalization methods using protein quantitative trait loci. 2025. bioRxiv. https:\/\/doi.org\/10.1101\/2025.11.07.686776.","DOI":"10.1101\/2025.11.07.686776"}],"container-title":["Cardiovascular Diabetology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12933-026-03209-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-026-03209-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-026-03209-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T02:03:18Z","timestamp":1783476198000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12933-026-03209-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,14]]},"references-count":98,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["3209"],"URL":"https:\/\/doi.org\/10.1186\/s12933-026-03209-w","relation":{},"ISSN":["1475-2840"],"issn-type":[{"value":"1475-2840","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,14]]},"assertion":[{"value":"19 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"UK Biobank received ethical approval from the National Information Governance Board for Health and Social Care and the National Health Service North West Centre for Research Ethics Committee (Ref: 21\/NW\/0157). All participants provided informed consent at recruitment to the study for their data to be used for health-related research that was in the public interest. The Lifelines protocol was approved by the UMCG Medical ethical committee under number 2007\/152. All participants signed an informed consent form. This study also used aggregated GWAS data, the underlying cohorts of which received ethical approval. We refer to the original GWAS for details (Table\u00a0\n                      \n                      ).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The work was carried out with unrestricted funding from NewAmsterdam Pharma, who are developing Obicetrapib, a CETP inhibiting agent. MD, JJPK are employed by New Amsterdam Pharma, as chief development officer, and chief scientific officer, respectively.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"196"}}